A one-day BioM and Lonza virtual symposium, to gain insight and discuss

BioM and Lonza are pleased to invite you to join them for a complimentary symposium, digitally delivered on 18 June 2020, to gain insight from experts, in the different approaches and techniques to successfully progress therapeutic proteins from discovery to the clinic.

Enjoy an industry perspective from a seasoned pharmaceutical executive, together with updates to approaches with new and established technologies enabling translational research, from Lonza specialists, local companies and leading academics.

Pre-book 1-on-1 sessions with our scientific experts at the Virtual Drop-in-Clinics that will follow the presentations.


Attendance at this event is complimentary and by invitation.
For more information, including the latest agenda and to register, please visit: http://www.bio-m.org/

Insight and discussion with our experts


09.00 – 09.10 Welcome:
Prof. Dr. Horst Domdey, CEO, BioM
Dr. Sarah Holland | Global Head of Licensing, Lonza
09.10 – 09.45 Keynote: An Industry perspective – What to consider when moving therapeutic proteins from development to first in human trials
Dr. Hari Kumar | Pharmaceutical Executive; Independent Board Member;
former CEO Adheron Therapeutics
09.45 – 10:20 Developability assessment tools and de-risking strategies to support progression of biologics from discovery to development
Dr. Noel Smith | Principal, Applied Protein Services, Lonza
10:20 – 10.45 PASylation®: an enabling technology to create biobetters with extended half-life and enhanced action
Prof. Dr. Arne Skerra | Chairman & Founder, XL-protein GmbH
10.45 – 11.00 Virtual coffee break
11.00 – 11.35 Approaches to maximise successful development of cell lines expressing more complex proteins – including bispecific antibodies
Dr. Alison Porter | Head of Expression System Sciences, Lonza
11.35 – 12.00 Antibodies against complex molecules
Dr. Annika Schmid | Associate Director, MorphoSys AG
12.00 – 12.35 A step forward – Combined strategies to enhance the performance of Pichia pastoris
Joachim Klein | Head of Strain Development and Cell Banking,
Microbial Development Services, Lonza
12.35 – 13.00 Accelerating a diverse pipeline of antibody-based medicines to the clinic
Dr. Carsten Brockmeyer | CEO, Formycon AG
13.00 – 13.30 Virtual lunch break
13.30 – 13.55 Dual-specific antibodies – Fusing tumor targeting and CD47 immune checkpoint blockade
Dr. Nadja Fenn | Project leader of the Exist-funded project OPSYON, Gene Center of the Ludwig-Maximilians University Munich
Virtual Drop-in-Clinics start
13.55 – 14.20 Anticalin® platform technology for innovative, cutting-edge protein therapeutics against respiratory diseases and cancer
Dr. Goran Martić | Senior Alliance Manager, Pieris Pharmaceuticals GmbH
Virtual Drop-in-Clinics continue
14.20 – 15.00 Q&A session with all speakers | Virtual Drop-in-Clinics continue
15.00 Virtual symposium ends | Virtual Drop-in-Clinics continue
  Register Here